drugset
drugset / Trial / NCT00228553

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

NCT00228553 ↗

Phase 3 Completed 743 enrolled Cephalon
Non-randomizedFactorialOpen-labelTreatment

Summary

A 12 Month, Open-Label, Flexible Dosage Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

Timeline

Start
2004-05
Primary completion
—
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Armodafinil Small molecule 100 mg —
Subject Armodafinil Small molecule 250 mg —

Indications

circadian rhythm sleep disorder, shift work type hypersomnia narcolepsy obstructive sleep apnea syndrome